|
Real-time Estimate
Cboe BZX
19:44:09 14/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 60.74 USD | +2.06% |
|
+4.14% | +38.85% |
| 10-09 | Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says | MT |
| 10-09 | RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating | MT |
Company Valuation: Exelixis, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,784 | 5,174 | 7,460 | 9,510 | 11,799 | 14,745 | - | - |
| Change | - | -10.54% | 44.19% | 27.47% | 24.07% | 24.97% | - | - |
| Enterprise Value (EV) 1 | 4,317 | 3,865 | 6,465 | 8,399 | 10,740 | 14,001 | 13,123 | 11,998 |
| Change | - | -10.45% | 67.25% | 29.91% | 27.88% | 30.36% | -6.27% | -8.57% |
| P/E | 25.4x | 28.6x | 36.9x | 18.9x | 15.8x | 18.4x | 15.2x | 11.5x |
| PBR | 2.64x | 2.09x | 3.21x | 4.18x | 5.32x | 5.66x | 4.16x | 3.09x |
| PEG | - | -1.3x | 2.3x | 0x | 0.3x | 1.1x | 0.7x | 0.4x |
| Capitalization / Revenue | 4.03x | 3.21x | 4.08x | 4.39x | 5.09x | 5.77x | 5.08x | 4.45x |
| EV / Revenue | 3.01x | 2.4x | 3.53x | 3.87x | 4.63x | 5.48x | 4.52x | 3.62x |
| EV / EBITDA | 14.4x | 17.4x | 32.9x | 13.3x | 11.9x | 12.8x | 10.3x | 7.52x |
| EV / EBIT | 15.1x | 19.2x | 37.8x | 13.9x | 12.3x | 13.6x | 10.2x | 7.61x |
| EV / FCF | 12.8x | 17.2x | 22.1x | 12.5x | 12.3x | 16.9x | 16.2x | 8.62x |
| FCF Yield | 7.8% | 5.8% | 4.53% | 8% | 8.15% | 5.9% | 6.19% | 11.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.72 | 0.56 | 0.65 | 1.76 | 2.78 | 3.232 | 3.919 | 5.188 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1,435 | 1,611 | 1,830 | 2,169 | 2,320 | 2,554 | 2,902 | 3,315 |
| EBITDA 1 | 300.3 | 222.4 | 196.6 | 633.4 | 901.2 | 1,091 | 1,279 | 1,595 |
| EBIT 1 | 286.7 | 201.5 | 170.9 | 604.6 | 872.2 | 1,031 | 1,286 | 1,576 |
| Net income 1 | 231.1 | 182.3 | 207.8 | 521.3 | 782.6 | 820.4 | 1,002 | 1,258 |
| Net Debt 1 | -1,467 | -1,308 | -995.3 | -1,111 | -1,059 | -744.5 | -1,623 | -2,747 |
| Reference price 2 | 18.28 | 16.04 | 23.99 | 33.30 | 43.83 | 59.51 | 59.51 | 59.51 |
| Nbr of stocks (in thousands) | 316,397 | 322,561 | 310,974 | 285,579 | 269,203 | 247,782 | - | - |
| Announcement Date | 17/02/22 | 07/02/23 | 06/02/24 | 11/02/25 | 10/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 18.42x | 5.48x | 12.83x | -.--% | 14.75B | |
| 20.44x | 7.28x | 14.62x | 1.45% | 70.44B | |
| 27.08x | 7.4x | 23.22x | 0.05% | 50.31B | |
| 33.03x | 5.94x | 17.79x | 0.98% | 47.51B | |
| 33.58x | 3.26x | 14.07x | -.--% | 42.91B | |
| -19.54x | 197.56x | -20.76x | -.--% | 40.39B | |
| 46.24x | 5.25x | 28.83x | -.--% | 39.69B | |
| 26.84x | 7.63x | 19.74x | 0.4% | 30.59B | |
| 30.94x | 6.59x | 17.1x | -.--% | 26.8B | |
| -13.49x | 4.97x | -6x | -.--% | 22.36B | |
| Average | 20.35x | 25.14x | 12.14x | 0.29% | 38.57B | |
| Weighted average by Cap. | 21.98x | 26.17x | 13.14x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EXEL Stock
- Valuation Exelixis, Inc.
Select your edition
All financial news and data tailored to specific country editions
